Pharmaceutical CEOs use earnings calls to criticize drug-pricing proposal

Executives at AbbVie, J&J, and Merck say the suggested changes in their current form would be 'chilling' or 'detrimental' to the development of new therapies.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.